UPMC Enterprises, the medical technology investment arm of UPMC, has purchased interest in RxAnte, a company that uses analytics to predict how patients will adhere to the medications they’re prescribed.
Read more on Pittsburgh Business Times.
Pittsburgh Business Times: UPMC Enterprises invests in prescription analytics company RxAnte
Related Resources
More Resources
02.12.19
Assessing the Value of Predictive Analytics for MAPD Plans
Blog Post
There’s a grossly unaddressed problem in the industry for Medicare Advantage Part D (MAPD) plans. That problem is the ambiguous role of “predictive analytics.” Well today, we’re throwing down the gauntlet and questioning the purpose and value of predictive analytics.
02.04.19
RxAnte Announces Partnership with Geisinger Health Plan to Drive Pharmacy Quality Strategy and Outcomes
Press Release
01.30.19
How MAPD Plans Can Achieve Successful Product Implementation
Blog Post
This week, our Vice President of Product Strategy and Management, gives Medicare Advantage Part D (MAPD) plans the low down on product implementation. Read on to get her tips on what to watch out for – and what to ask for – to ensure success with health tech partners as you gear up for new ways to beat cut points in 2019 and beyond.